H. Raab

Nature Biotechnology · 2008–2015

A researcher in the Science corpus: 4 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Who trusts H. Raab overall

  1. Paul Polakis

Papers from H. Raab's perspective

Ordered by how strongly the researchers H. Raab trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Arming antibodies: prospects and challenges for immunoconjugates (Nature Biotechnology)
  2. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index (Nature Biotechnology)
  3. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (Cancer Research)
  4. Targeted cancer therapy: conferring specificity to cytotoxic drugs. (Accounts of Chemical Research)
  5. Monoclonal antibody successes in the clinic (Nature Biotechnology)
  6. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (Nature Biotechnology)
  7. A history of cancer chemotherapy. (Cancer Research)
  8. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (Nature Biotechnology)
  9. An enhanced system for unnatural amino acid mutagenesis in E. coli. (Journal of Molecular Biology)
  10. Antibody Drug Conjugates for Cancer Therapy (Pharmacological Reviews)

Their papers